donepezil has been researched along with Atrophy in 25 studies
Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.
donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.
2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study investigated whether donepezil exerts symptomatic benefit in patients with posterior cortical atrophy (PCA), an atypical variant of Alzheimer's disease." | 9.27 | A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study. ( Barker, S; Crutch, S; Cutler, D; Douglas, J; Epie, N; Frost, C; Knight, W; Kukkastenvehmas, R; Ridha, BH; Rossor, MN; Warrington, EK, 2018) |
| "The purpose of this study was to study the effect of donepezil on the rate of hippocampal atrophy in prodromal Alzheimer's disease (AD)." | 9.20 | Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. ( Ait Ameur, A; Bonafe, A; Cavedo, E; Ceccaldi, M; Chupin, M; Colliot, O; Croisile, B; Delmaire, C; Dormont, D; Dubois, B; Dufouil, C; Duveau, F; Garnero, L; Girard, N; Hampel, H; Lehericy, S; Lista, S; Louis Tisserand, G; Ousset, PJ; Pasquier, F; Ricolfi, F; Rouaud, O; Sarazin, M; Tonelli, I; Touchon, J; Vighetto, A, 2015) |
| " Upon analysis of covariance, where those confounding variables (age, sex, disease duration, education, MRI interval, APOE genotype, and baseline Alzheimer's Disease Assessment Scale score) were entered into the model as covariates, the effect of donepezil treatment on hippocampal atrophy remained significant." | 9.11 | Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? ( Hashimoto, M; Kazui, H; Matsumoto, K; Mori, E; Nakano, Y; Yasuda, M, 2005) |
| "To investigate whether atrophy of the substantia innominata as shown on magnetic resonance imaging (MRI), reflecting degeneration of cholinergic neurons in the nucleus basalis of Meynert, predicts response to donepezil treatment in patients with Alzheimer's disease (AD), we studied correlations between the thickness of the substantia innominata and clinical efficacy." | 7.72 | Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients. ( Abe, K; Hanyu, H; Sakurai, H; Takasaki, M; Tanaka, Y, 2003) |
| "Donepezil administered at a prodromal stage of AD seems to substantially reduce the rate of atrophy of the BFCS nuclei with highest concentration of cholinergic neurons projecting to the cortex (NbM), hippocampus and entorhinal cortex (Ch1/2)." | 6.84 | Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. ( Cavedo, E; Chupin, M; Colliot, O; Dormont, D; Dubois, B; Grothe, MJ; Hampel, H; Houot, M; Lehéricy, S; Lista, S; Teipel, S, 2017) |
| "Donepezil-treated MCI individuals showed slower atrophy rates compared to the placebo group, but only if they belonged to the minimal atrophy or hippocampal-sparing subtypes." | 5.69 | Differential response to donepezil in MRI subtypes of mild cognitive impairment. ( Cavedo, E; Diaz-Galvan, P; Dubois, B; Ferreira, D; Grothe, MJ; Hampel, H; Kantarci, K; Lista, S; Lorenzon, G; Mårtensson, G; Mohanty, R; Vergallo, A; Westman, E, 2023) |
| "Treatment with donepezil did not alter the progression of hippocampal deformation in subjects with DAT in this study." | 5.36 | Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. ( Csernansky, JG; Galvin, JE; Harms, MP; Morris, JC; Staggs, JM; Wang, L; Xiong, C, 2010) |
| "The study investigated whether donepezil exerts symptomatic benefit in patients with posterior cortical atrophy (PCA), an atypical variant of Alzheimer's disease." | 5.27 | A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study. ( Barker, S; Crutch, S; Cutler, D; Douglas, J; Epie, N; Frost, C; Knight, W; Kukkastenvehmas, R; Ridha, BH; Rossor, MN; Warrington, EK, 2018) |
| "The purpose of this study was to study the effect of donepezil on the rate of hippocampal atrophy in prodromal Alzheimer's disease (AD)." | 5.20 | Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease. ( Ait Ameur, A; Bonafe, A; Cavedo, E; Ceccaldi, M; Chupin, M; Colliot, O; Croisile, B; Delmaire, C; Dormont, D; Dubois, B; Dufouil, C; Duveau, F; Garnero, L; Girard, N; Hampel, H; Lehericy, S; Lista, S; Louis Tisserand, G; Ousset, PJ; Pasquier, F; Ricolfi, F; Rouaud, O; Sarazin, M; Tonelli, I; Touchon, J; Vighetto, A, 2015) |
| "A 3-year, double-blind, placebo-controlled Alzheimer's Disease Cooperative Study initially designed to evaluate the efficacy of donepezil hydrochloride or vitamin E vs placebo to delay progression of MCI to dementia." | 5.12 | Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. ( Clark, CM; DeCarli, C; Frisoni, GB; Grundman, M; Harvey, D; Jack, CR; Jin, S; Petersen, RC; Scheltens, P; Thal, LJ, 2007) |
| " Upon analysis of covariance, where those confounding variables (age, sex, disease duration, education, MRI interval, APOE genotype, and baseline Alzheimer's Disease Assessment Scale score) were entered into the model as covariates, the effect of donepezil treatment on hippocampal atrophy remained significant." | 5.11 | Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? ( Hashimoto, M; Kazui, H; Matsumoto, K; Mori, E; Nakano, Y; Yasuda, M, 2005) |
| "To investigate whether atrophy of the substantia innominata as shown on magnetic resonance imaging (MRI), reflecting degeneration of cholinergic neurons in the nucleus basalis of Meynert, predicts response to donepezil treatment in patients with Alzheimer's disease (AD), we studied correlations between the thickness of the substantia innominata and clinical efficacy." | 3.72 | Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients. ( Abe, K; Hanyu, H; Sakurai, H; Takasaki, M; Tanaka, Y, 2003) |
| "Donepezil administered at a prodromal stage of AD seems to substantially reduce the rate of atrophy of the BFCS nuclei with highest concentration of cholinergic neurons projecting to the cortex (NbM), hippocampus and entorhinal cortex (Ch1/2)." | 2.84 | Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. ( Cavedo, E; Chupin, M; Colliot, O; Dormont, D; Dubois, B; Grothe, MJ; Hampel, H; Houot, M; Lehéricy, S; Lista, S; Teipel, S, 2017) |
| "Donepezil is an acetylcholinesterase inhibitor used to treat Alzheimer's disease (AD)." | 1.40 | The potentially protective effect of donepezil in Alzheimer's disease. ( Ishiwata, A; Katayama, Y; Mishina, M; Mizumura, S; Yamazaki, M, 2014) |
| "Treatment with donepezil did not alter the progression of hippocampal deformation in subjects with DAT in this study." | 1.36 | Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease. ( Csernansky, JG; Galvin, JE; Harms, MP; Morris, JC; Staggs, JM; Wang, L; Xiong, C, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (48.00) | 29.6817 |
| 2010's | 12 (48.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Diaz-Galvan, P | 1 |
| Lorenzon, G | 1 |
| Mohanty, R | 1 |
| Mårtensson, G | 1 |
| Cavedo, E | 3 |
| Lista, S | 3 |
| Vergallo, A | 1 |
| Kantarci, K | 1 |
| Hampel, H | 3 |
| Dubois, B | 3 |
| Grothe, MJ | 2 |
| Ferreira, D | 1 |
| Westman, E | 1 |
| Yokoyama, S | 1 |
| Yoshinaga, T | 1 |
| Matsuzaki, J | 1 |
| Suzuki, H | 1 |
| Colliot, O | 2 |
| Chupin, M | 2 |
| Dormont, D | 2 |
| Houot, M | 1 |
| Lehéricy, S | 2 |
| Teipel, S | 1 |
| Ridha, BH | 1 |
| Crutch, S | 1 |
| Cutler, D | 1 |
| Frost, C | 1 |
| Knight, W | 1 |
| Barker, S | 1 |
| Epie, N | 1 |
| Warrington, EK | 1 |
| Kukkastenvehmas, R | 1 |
| Douglas, J | 1 |
| Rossor, MN | 1 |
| Ishiwata, A | 1 |
| Mizumura, S | 1 |
| Mishina, M | 1 |
| Yamazaki, M | 1 |
| Katayama, Y | 1 |
| Croisile, B | 1 |
| Louis Tisserand, G | 1 |
| Touchon, J | 1 |
| Bonafe, A | 1 |
| Ousset, PJ | 1 |
| Ait Ameur, A | 1 |
| Rouaud, O | 1 |
| Ricolfi, F | 1 |
| Vighetto, A | 1 |
| Pasquier, F | 1 |
| Delmaire, C | 1 |
| Ceccaldi, M | 1 |
| Girard, N | 1 |
| Dufouil, C | 1 |
| Tonelli, I | 1 |
| Duveau, F | 1 |
| Garnero, L | 1 |
| Sarazin, M | 1 |
| Tagawa, R | 1 |
| Hashimoto, H | 1 |
| Nakanishi, A | 1 |
| Kawarada, Y | 1 |
| Muramatsu, T | 1 |
| Matsuda, Y | 1 |
| Kataoka, K | 1 |
| Shimada, A | 1 |
| Uchida, K | 1 |
| Yoshida, A | 1 |
| Higashiyama, S | 1 |
| Kawabe, J | 1 |
| Kai, T | 1 |
| Shiomi, S | 1 |
| Mori, H | 1 |
| Inoue, K | 1 |
| Balasubramaniam, SC | 1 |
| Chen, JJ | 1 |
| Thomas Antérion, C | 1 |
| Convers, P | 1 |
| Desmales, S | 1 |
| Borg, C | 1 |
| Laurent, B | 1 |
| van Straaten, EC | 1 |
| Harvey, D | 2 |
| Scheltens, P | 2 |
| Barkhof, F | 1 |
| Petersen, RC | 3 |
| Thal, LJ | 3 |
| Jack, CR | 3 |
| DeCarli, C | 2 |
| Kurota, S | 1 |
| Wang, L | 1 |
| Harms, MP | 1 |
| Staggs, JM | 1 |
| Xiong, C | 1 |
| Morris, JC | 1 |
| Csernansky, JG | 1 |
| Galvin, JE | 1 |
| Suda, S | 1 |
| Sugihara, G | 1 |
| Suyama, R | 1 |
| Mori, N | 1 |
| Takei, N | 1 |
| Peter, F | 1 |
| Susanne, J | 1 |
| Margareta, H | 1 |
| Silvia, W | 1 |
| Wolfgang, K | 1 |
| Thomas, L | 1 |
| Heinz, TK | 1 |
| Bottini, G | 1 |
| Berlingeri, M | 1 |
| Basilico, S | 1 |
| Passoni, S | 1 |
| Danelli, L | 1 |
| Colombo, N | 1 |
| Sberna, M | 1 |
| Franceschi, M | 1 |
| Sterzi, R | 1 |
| Paulesu, E | 1 |
| Hayashi, H | 1 |
| Kawakatsu, S | 1 |
| Suzuki, A | 1 |
| Shibuya, Y | 1 |
| Kobayashi, R | 1 |
| Sato, C | 1 |
| Otani, K | 1 |
| Tanaka, Y | 2 |
| Hanyu, H | 2 |
| Sakurai, H | 2 |
| Takasaki, M | 2 |
| Abe, K | 2 |
| Hashimoto, M | 1 |
| Kazui, H | 1 |
| Matsumoto, K | 1 |
| Nakano, Y | 1 |
| Yasuda, M | 1 |
| Mori, E | 1 |
| Bourgeois, JA | 1 |
| Farzin, F | 1 |
| Brunberg, JA | 1 |
| Tassone, F | 1 |
| Hagerman, P | 1 |
| Zhang, L | 1 |
| Hessl, D | 1 |
| Hagerman, R | 1 |
| Frisoni, GB | 1 |
| Clark, CM | 1 |
| Grundman, M | 2 |
| Jin, S | 2 |
| Gamst, A | 1 |
| Ward, CP | 1 |
| Sencakova, D | 1 |
| Doody, RS | 1 |
| Spiessl, H | 1 |
| Marienhagen, J | 1 |
| Stöhr, H | 1 |
| Klein, HE | 1 |
| Kawashima, T | 1 |
| Yamada, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Trial of Vitamin E and Donepezil HCL (Aricept) to Delay Clinical Progression From Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)[NCT00000173] | Phase 3 | 0 participants | Interventional | 1999-03-31 | Completed | ||
| A 36-month, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment (MCI)[NCT01429623] | Phase 2 | 210 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| Namenda as Prevention for Post-Operative Delirium[NCT00303433] | Phase 4 | 30 participants | Interventional | 2006-03-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean value change (from baseline) in Disability Assessment in Dementia (DAD) across entire study period. DAD evaluates the basic and instrumental activities in daily activities of elderly people with dementia. Higher scores reflect better functioning. DAD ranges from 0 to 100. (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Change from basline on units on a scale (Mean) |
|---|---|
| Ladostigil Hemitartrate | -0.77 |
| Placebo Control | -0.40 |
"Mean value change (from baseline) in Geriatric Depression Scale (GDS) across entire study period. The GDS ranges from 0 to 30. Scores of 0-9 are considered normal, 10-19 mildly depressed, and 20-30 severely depressed." (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Change from basline on units on a scale (Mean) |
|---|---|
| Ladostigil Hemitartrate | .084 |
| Placebo Control | .242 |
Mean value change (from baseline) in Neuropsychiatric Test Battery (NTB) across entire study period. The NTB included the following well known cognitive tests: Rey Auditory Verbal Learning Test (RAVLT), Controlled Word Association Test (COWAT), Category Fluency Test (CFT), WMS-R Digit Span, and Trail Making Part A and B. The mean value was comprised of the z score of each of these tests with all z scores in the direction of higher scores better functioning. Range -3 to +3. (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Change from basline on units on a scale (Mean) |
|---|---|
| Ladostigil Hemitartrate | .21 |
| Placebo Control | .17 |
"Total number of conversions from Mild Cognitive Impairment to Alzheimer's disease across entire 3 year study period. Conversion is determined, or defined, by a Clinical Dementia Rating (CDR) score of greater than or equal to one.~Composite rating ranges from 0 no symptoms of dementia to 3 Severe symptoms of dementia." (NCT01429623)
Timeframe: 3,6,12,18,24,30 and 36 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Ladostigil Hemitartrate | 14 |
| Placebo Control | 21 |
1 review available for donepezil and Atrophy
| Article | Year |
|---|---|
[Clinical and pathological findings in dementia with Lewy bodies].
Topics: Aged; Atrophy; Brain; Cholinesterase Inhibitors; Diagnosis, Differential; Diagnostic Imaging; Donepe | 2008 |
10 trials available for donepezil and Atrophy
| Article | Year |
|---|---|
Differential response to donepezil in MRI subtypes of mild cognitive impairment.
Topics: Alzheimer Disease; Atrophy; Cognitive Dysfunction; Donepezil; Humans; Magnetic Resonance Imaging | 2023 |
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Teprenone in Patients with Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Anti-Ulcer Agents; Atrophy; Cognition; Diterpenes; Donepezil; Double-Blind | 2019 |
Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Atrophy; Basal Forebrain; Cholinergic Neurons; Disease Progression; Donepez | 2017 |
A double-blind placebo-controlled cross-over clinical trial of DONepezil In Posterior cortical atrophy due to underlying Alzheimer's Disease: DONIPAD study.
Topics: Aged; Alzheimer Disease; Atrophy; Cerebral Cortex; Cholinesterase Inhibitors; Cross-Over Studies; Do | 2018 |
Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Atrophy; Disease Progression; Donepezil; Double-Blind Method; Female; Franc | 2015 |
Periventricular white matter hyperintensities increase the likelihood of progression from amnestic mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Antioxidants; Atrophy; Brain; Cerebral Ventricl | 2008 |
Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease?
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Atrophy; Cholinesterase Inhibitors; Cohort Studies; Dise | 2005 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia.
Topics: Aged; Aged, 80 and over; Atrophy; Cognition Disorders; Dementia; Disease Progression; Donepezil; Dou | 2007 |
Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI.
Topics: Aged; Aged, 80 and over; Antioxidants; Atrophy; Cholinesterase Inhibitors; Cognition Disorders; Done | 2008 |
Atrophy of the substantia innominata on magnetic resonance imaging and response to donepezil treatment in Alzheimer's disease.
Topics: Acetylcholine; Aged; Alzheimer Disease; Atrophy; Cholinergic Fibers; Cholinesterase Inhibitors; Done | 2002 |
14 other studies available for donepezil and Atrophy
| Article | Year |
|---|---|
The potentially protective effect of donepezil in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atrophy; Case-Control Studies; Donepezil; Female; Hippoc | 2014 |
The Relationship Between Medial Temporal Lobe Atrophy and Cognitive Impairment in Patients With Dementia With Lewy Bodies.
Topics: Age of Onset; Aged; Aged, 80 and over; Alzheimer Disease; Amygdala; Atrophy; Cognition Disorders; Do | 2015 |
Unexplained Homonymous Hemianopia.
Topics: Alzheimer Disease; Atrophy; Cholinesterase Inhibitors; Donepezil; Female; Hemianopsia; Humans; Indan | 2016 |
An odd manifestation of the Capgras syndrome: loss of familiarity even with the sexual partner.
Topics: Aged; Amnesia; Antipsychotic Agents; Atrophy; Brain; Capgras Syndrome; Donepezil; Hallucinations; Hu | 2008 |
Donepezil treatment and changes in hippocampal structure in very mild Alzheimer disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain Mapping; Cholinesterase Inhibitors; Cognition Disorders; Coh | 2010 |
Donepezil and concurrent sertraline treatment is associated with increased hippocampal volume in a patient with depression.
Topics: Adult; Alzheimer Disease; Atrophy; Cholinesterase Inhibitors; Cognition Disorders; Depressive Disord | 2010 |
"Reversible" Alzheimer's disease?
Topics: Aged; Alzheimer Disease; Atrophy; Cohort Studies; Combined Modality Therapy; Donepezil; Female; Fluo | 2011 |
GOOD or BAD responder? Behavioural and neuroanatomical markers of clinical response to donepezil in dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atrophy; Biomarkers; Brain; Cholinesterase Inhibitors; D | 2012 |
Application of the VSRAD, a specific and sensitive voxel-based morphometry, to comparison of entorhinal cortex atrophy between dementia with Lewy bodies and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atrophy; Data Interpretation, Statistical; Donepezil; En | 2012 |
Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Atrophy; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Logi | 2003 |
Dementia with mood symptoms in a fragile X premutation carrier with the fragile X-associated tremor/ataxia syndrome: clinical intervention with donepezil and venlafaxine.
Topics: Aged; Antidepressive Agents, Second-Generation; Ataxia; Atrophy; Brain; Cyclohexanols; Dementia; Dom | 2006 |
Drug may slow brain shrinkage in pre-Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Atrophy; Brain; Cognition Disorders; Disease Progression; Donepezil; Humans | 2006 |
[Aphasia and dementia].
Topics: Aged; Aphasia, Primary Progressive; Atrophy; Brain; Dementia; Diagnosis, Differential; Donepezil; Fe | 2001 |
Delirium caused by donepezil: a case study.
Topics: Aged; Alzheimer Disease; Atrophy; Cerebral Cortex; Delirium; Donepezil; Humans; Indans; Male; Nootro | 2002 |